| 柏朋刚,李奇欣,陈开强,等.COMPASS系统在鼻咽癌容积旋转调强剂量验证中的应用[J].中华放射医学与防护杂志,2012,32(3):304-307.BAI Peng-gang,LI Qi-xin,CHEN Kai-qiang,et al.Dosimetric verification of volumetric modulated arc therapy in nasopharyngeal carcinoma using COMPASS 3D patient anatomy based system[J].Chin J Radiol Med Prot,2012,32(3):304-307 |
| COMPASS系统在鼻咽癌容积旋转调强剂量验证中的应用 |
| Dosimetric verification of volumetric modulated arc therapy in nasopharyngeal carcinoma using COMPASS 3D patient anatomy based system |
| 投稿时间：2011-07-21 |
| DOI：10.3760/cma.j.issn.0254-5098.2012.03.021 |
| 中文关键词: COMPASS系统 容积旋转调强 剂量验证 |
| 英文关键词:COMPASS system Volumetric modulated arc therapy Dosimetric verification |
| 基金项目: |
|
| 摘要点击次数: 5373 |
| 全文下载次数: 2768 |
| 中文摘要: |
| 目的 探讨COMPASS三维剂量验证系统在鼻咽癌容积旋转调强剂量验证中的应用。方法 选取8例鼻咽癌病例在Masterplan治疗计划系统中进行旋转调强计划设计,然后将治疗计划分别传输至COMPASS系统和控制加速器运行的MOSAIQ网络上。比较计划系统计算结果和COMPASS实际测量结果差异的主要指标,如靶区的平均剂量(Dmean)、95%体积剂量(D95%)和γ值,脊髓、脑干的Dmean和D1%,左右腮腺的Dmean、V30。结果 计划系统计算结果和COMPASS实际测量的结果二者在靶区的γ通过率均＞95%,各个靶区的D95%平均偏差大多<3%,各个靶区Dmean的偏差平均值在1%以内。脊髓和脑干的D1%的平均偏差分别为(4.3±3.0)%和(5.9±2.9)%,二者Dmean的平均偏差分别为(5.3±3.0)%和(8.0±3.5)%。COMPASS测量的脊髓和脑干的剂量都比计划系统计算的结果小。左右腮腺Dmean差异的平均值分别为(6.1±3.1)%、(4.7±4.4)%,V30的差异分别为(9.4±7.5)%和(9.4±9.9)%。结论 COMPASS三维剂量验证系统是容积旋转调强剂量验证的一个非常理想的工具,可以快速、直观地分析出靶区和正常器官理论和实际照射情况下的差异。 |
| 英文摘要: |
| Objective To investigate the dosimetric performance of COMPASS system, a novel 3D quality assurance system for the verification of nasopharyngeal carcinoma volumetric modulated therapy (VMAT) treatment plan.Methods Eight VMAT treatment plans of nasopharyngeal carcinoma patients were performed with MasterPlan, a treatment planning system (TPS), and then these treatment plans were sent to the COMPASS and MOSAIQ system, a coherent control system, respectively. Comparison of the COMPASS reconstructed dose versus TPS dose was conducted by using the dose volume-based indices: dose received by 95% volume of target (D95%), mean dose (Dmean) and γ pass rate, dose to the 1% of the spinal cord and brain stem volume (D1%), mean dose of leaf and right parotid (Dmean), and the volume received 30 Gy for left and right parotid (V30). COMPASS can reconstruct dose with the real measured delivery fluence after detector commissioning.Results The average dose difference for the target volumes was within 1%, the difference for D95 was within 3% for most treatment plans, and the γ pass rate was higher than 95% for all target volumes. The average differences for the D1% values of spinal cord and brain stem were (4.3±3.0)% and (5.9±2.9)% respectively, and the average differences for the Dmean values of spinal cord and brain stem were (5.3±3.0)% and (8.0±3.5)% respectively. In general the COMPASS measured doses were all smaller than the TPS calculated doses for these two organs. The average differences of the Dmean values of the left and right parotids were (6.1±3.1)% and(4.7±4.4)% respectively, and the average differences of the V30 values of the left and right parotids were (9.4±7.5)% and (9.4±9.9)% respectively.Conclusions An ideal tool for the VMAT verification, the patient anatomy based COMPASS 3D dose verification system can check the dose difference between the real delivery and TPS calculation directly for each individual organ, either target volumes or critical organs. |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|